Definiens, MolecularMD Partner to Provide Quantitative Tissue Assays for Oncology | GenomeWeb

NEW YORK (GenomeWeb) –Definiens and MolecularMD said today that they will partner to provide customized diagnostic solutions in oncology.

Definiens specializes in what it calls "tissue phenomics" for biomarker and companion diagnostics development and commercialization. MolecularMD develops custom molecular diagnostic products and supports clinical trial services for targeted cancer therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.

Sponsored by

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.


This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.